What's in Avistone Biotechnology Co., Ltd.'s pipeline?

Avistone Biotechnology Co., Ltd. has 4 drugs in our index: 0 marketed, 0 filed, 2 in Phase 3, 0 in Phase 2, 2 in Phase 1.

Which companies overlap with Avistone Biotechnology Co., Ltd.'s portfolio?

No competitive overlap detected.

How do I subscribe to ongoing alerts?

Subscribe to /feed/company/avistone-biotechnology-co-ltd.xml in any RSS reader. Every regulatory action and pipeline update lands in your feed.

Last reviewed 2026-05-16 · How we verify

Avistone Biotechnology Co., Ltd. — Portfolio Competitive Intelligence Brief

Avistone Biotechnology Co., Ltd. pipeline: 0 marketed, 0 filed, 2 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

0 marketed 0 filed 2 Phase 3 0 Phase 2 2 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

Drug	Generic	Phase	Class	Target	Area	First approval
Pemetrexed plus Carboplatin or Cisplatin	Pemetrexed plus Carboplatin or Cisplatin	phase 3	Antifolate antimetabolite combined with platinum-based chemotherapy	Thymidylate synthase, dihydrofolate reductase, glycinamide ribonucleotide formyltransferase; DNA (platinum agents)	Oncology
PLB1004	PLB1004	phase 3

Therapeutic area mix

Oncology · 1

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

No competitive overlap data.

Subscribe to ongoing alerts

Every new pipeline event for Avistone Biotechnology Co., Ltd.:

Cite this brief

Drug Landscape (2026). Avistone Biotechnology Co., Ltd. — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/avistone-biotechnology-co-ltd. Accessed 2026-05-16.